P513 The effect of intravenous iron treament on quality of life in Inflammatory Bowel Disease patients with non-anemic iron deficiency
C. Çekiç*, F. Aslan, M. Arabul, S. Ipek, E.S. Yüksel, E. Alper, Z. Akpinar, B. Unsal
Katip Çelebi University, Atatürk Training and Research Hospital, Gastroenterology, Izmir, Turkey
Iron deficiency is the most prevalent systemic complication of inflammatory bowel disease (IBD). Herein, we investigated the effect of intravenous iron treatment on quality of life (QoL) in non-anemic IBD patients.
Eighty-five IBD patients (55 ulcerative colitis, 30 Crohn's disease) who were non-anemic and in remission were recruited for this prospective study. The patients were intravenously administered 500 mg iron sucrose (FeS) in the first week of the study. Hematologic parameters and QoL were evaluated before prior to iron treatment and during the 12th week of treatment. The Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36) Health Survey (version 2) were used to assess QoL.
Prior to intravenous iron administration, the IBDQ, SF-36 Physical Component Summary and Mental Component Summary scores were 152.3 ± 30.6, 46.7 ± 7.3, and 45.7 ± 9.8, respectively. In the 12th week of iron administration, those scores were 162.3 ± 25.5 (p<0.001), 49.3 ± 6.4 (p<0.001), and 47.6 ± 8.9 (p=0.024), respectively, which were all significantly different from the scores prior to iron administration. The mean changes in the IBDQ scores for ulcerative colitis and Crohn's disease were 8.7% and 3.0% (p=0.029), were 6.4% and 4.7% (p=0.562) for the SF-36 Physical Component Summary, and were 4.6% and 3.2% (p=0.482) for the SF-36 Mental Component Summary, respectively.
Intravenous iron treatment may improve QoL in non-anemic, but iron deficient, IBD patients.